The inhibitory glycine receptor (GlyR) is a key mediator of synaptic signaling in spinal cord, brain stem, and higher central nervous system regions. The flavonoids quercetin and genistein have been identified previously as promising GlyR antagonists in vitro, but their detailed mechanism of action was not known. Here, inhibition of recombinant human a1 GlyRs in HEK 293 cells by genistein, quercetin, and strychnine was studied using whole-cell recording techniques. The interaction of several inhibitors applied alone or in combination was analyzed using a minimum mechanism of receptor activation and inhibition. Receptor inhibition in vivo was studied in a mouse model of strychnine toxicity. Genistein, quercetin, and strychnine were noncompetitive GlyR inhibitors. The inhibitory potency of one flavonoid (either genistein or quercetin) was not affected by simultaneous application of the other, suggesting that both flavonoids target the same site on the receptor. In combination with strychnine, flavonoid inhibition was augmented, indicating that strychnine binds to a position on the receptor physically distant from the flavonoid site. Potentiation of strychnine inhibition by flavonoids was also observed in vivo, where harmless doses of flavonoids enhanced strychnine toxicity in mice. Thus, in vitro and in vivo studies demonstrated a true synergism between flavonoids and strychnine for GlyR inhibition. The mechanismbased approach used here allows a rapid analysis of the effects of single drugs versus drug combinations.
The inhibitory glycine receptor (GlyR) is a member of the cysteine loop superfamily of ligand-gated ion channel receptors. It shares structural similarity with nicotinic acetylcholine, c-aminobutyric acid A (GABA A ), and serotonin (5-HT 3 ) receptors (Breitinger and Becker, 2002a; Lynch, 2004 Lynch, , 2009 ). The GlyR is mainly expressed in spinal cord, brain stem, and other regions of the central nervous system, where it mediates rapid synaptic inhibition (Betz et al., 1994; Breitinger and Becker, 2002a; Legendre, 2001; Lynch, 2004 Lynch, , 2009 . GlyRs are homo-or heteromeric pentamers composed of a (a 1 -a 4 ) and b subunits (Betz, 1991; Betz et al., 1994; Breitinger and Becker, 1998, 2002a; Lynch, 2009; Malosio et al., 1991) . Each subunit consists of a large N-terminal extracellular domain, followed by four transmembrane domains (TM1-TM4), and an extracellular C-terminus. TM2 forms the inner lining of the ion pore, ligand-binding sites are thought to be located at subunit interfaces in the N-terminal domain from where they mediate open-close transitions to the TM2 domain (Betz, 1991; Betz et al., 1994; Breitinger and Becker, 1998, 2002a; Lynch, 2009; Malosio et al., 1991; Rajendra et al., 1997) .
Flavonoids exhibit numerous biological and pharmacological effects, including antioxidant, anti-inflammatory, and anticarcinogenic (Kandaswami and Middleton, 1994; Kandaswami et al., 1992; Middleton et al., 2000) , as well as cardioprotective, bacteriostatic, and secretory properties (Harborne and Williams, 2000; Havsteen, 2002; Huang et al., 1999; Kandaswami and Middleton, 1994; Kuhnau, 1976) . Some synthetic flavonoids have been reported as GABA A receptor ligands (Griebel et al., 1999; Marder et al., 2001; Salgueiro et al., 1997) . Quercetin (Fig. 1A) is mainly found in apple, tomato, gingko, and other red colored fruit. It belongs among a broad group of polyphenolic flavonoid substances (Kuhnau, 1976; Morand et al., 1998) and has a wide range of biological activities. These include neuropharmacological actions such as analgesia, mild sedation (Picq et al., 1991) , and modulation of oxidative metabolism in neurons (Oyama et al., 1994) . Quercetin was found to be a tyrosine kinase inhibitor (Huang et al., 1999; Lee et al., 2002) , as well as an inhibitor of glycine-and serotonin 5-HT 3 receptor-mediated currents (Lee et al., 2007; Lee et al., 2008) . Genistein (Fig. 1B) , a tyrosine kinase inhibitor, is a naturally occurring polyphenol from soybean. It was found to decrease the excitability of capsaicin-sensitive nociceptive neurons, with much of this decrease occurring as a consequence of its inhibition of voltage-gated sodium channels (Liu et al., 2004) . Genistein was also reported to directly inhibit the GlyR, independent of its effects on protein tyrosine kinase (Huang and Dillon, 2000) . A mutagenesis study (Lee et al., 2007) suggested that GlyR inhibition by quercetin is sensitive to mutations in position GlyR a1(S267), the same residue that has also been implicated in the actions of alcohols (Dibas et al., 2002; Ye et al., 1998) and picrotoxin (Dibas et al., 2002; Ye et al., 1998) Here, we examined the mechanism of GlyR inhibition by quercetin, genistein, and strychnine employing patch-clamp methods and fast ligand application. Using a mechanism-based approach, synergism of inhibition resulting from the coapplication of the flavonoids together with strychnine was observed. Similar inhibitory patterns were found in vivo, where the synergistic mode of inhibition could be confirmed in behavioral tests on mice.
MATERIALS AND METHODS
Cell culture and maintenance. HEK 293 cells were used for patch-clamp experiments. This line was generated in the 1970's by transforming human embryonic kidney cells with adenovirus 5 DNA. They are easily cultured and transfected and are a standard tool for the expression of many proteins including transmembrane receptors. HEK 293 cells were obtained from the Health Protection Agency European Cell Culture collection (Salisbury, UK). Cells were grown in 10-cm tissue culture dishes at 37°C, 5% CO 2 , in a saturated water atmosphere, cultivated in minimum essential medium, supplemented with 10% fetal bovine serum (Invitrogen, Karlsruhe, Germany), 100 IU penicillin, 100 lg/l streptomycin (Sigma), and passaged twice weekly. On the day of transfer, cells were plated onto poly-L-lysine (Sigma-Aldrich, Taufkirchen, Germany)-coated glass plates in 60-mm petri dishes. Cells were transfected using Metafectene (Biontex, Martinsried, Germany) and 1 lg of GlyR complementary DNA (gift from C.-M. Becker, Institute for Biochemistry, University of Erlangen) per 60-mm dish and cotransfected with green fluorescent protein for identification of positive transfectants. Transfected cells were used for experiments within 2-5 days.
Whole-cell recording. Voltage-clamp recordings from transfected HEK-293 cells were performed in the whole-cell configuration. Pipettes were pulled using a Sutter P-97 Flaming/Brown Micropipette Puller (Sutter Instruments, Novato, CA). The extracellular buffer consisted of 137mM NaCl, 5.4mM KCl, 1.8mM CaCl 2 , 1.0mM MgCl 2 , and 10.0mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES), pH 7.4, and the intracellular buffer was 120mM CsCl, 20mM, N(Et) 4 Cl, 1.0mM CaCl 2 , 2.0mM MgCl 2 , 5.0mM ethyleneglycol bis(b-aminoethyl ether)-N,N,N#,N#-tetraacetic acid, and 10.0mM HEPES, pH 7.4. All agonist and inhibitor solutions were prepared freshly every day. Stock solutions in extracellular buffer were 1mM (quercetin, genistein, and strychnine) and 100mM (glycine), these could be kept at À20°C for several weeks without loss of activity.
All measurements were carried out at 21-23°C, at a transmembrane voltage of À60 mV. Whole-cell currents were acquired with an EPC 10 patch-clamp amplifier (HEKA Instruments, Lambrecht, Germany), filtered at 3 kHz with a low-pass Bessel filter and stored on a PC for offline analysis using Microcal Origin (Microcal, Northampton, MA).
Current recordings from each cell were normalized to the response measured with 2000lM glycine. Dose-response analysis of glycine-mediated currents was done using the Hill equation:
; where I Gly is the peak current elicited by a given glycine concentration, I sat is the maximum observed whole-cell current amplitude produced by a saturating glycine concentration, [Gly] is the glycine concentration, EC 50 is the glycine concentration eliciting a half-maximum response, and n H is the Hill coefficient. Dose-inhibition curves were constructed for glycine-activated currents obtained in the absence (I Gly ) and the presence (I inh ) of various concentrations of inhibitors and fitted with the equation:
Here, I inh is the amount of glycine current produced by a given glycine concentration in the presence of an inhibitor, I Gly is the current elicited by the same glycine concentration in the absence of the inhibitor, [inh] is the concentration of inhibitor, IC 50 is the inhibitor concentration that produces halfmaximal inhibition, and n H is the Hill coefficient for the inhibition. by guest on October 17, 2010 toxsci.oxfordjournals.org
Downloaded from
Values for K i , the affinity of inhibitors to the GlyR, were estimated from the Cheng-Prusoff equation:
where IC 50 is the concentration of half-maximal inhibition at a given glycine concentration, [gly] is the concentration of glycine at which IC 50 was determined, and EC 50 is as defined above. Mechanistic analysis of whole-cell current data was done according to the equations derived in the Appendix. All constants obtained from curve fitting are given as means ± SD. Statistical significance was determined by one-way ANOVA with p < 0.05 representing significance.
Behavioral studies. Male Swiss-Webster mice (El-Skary Animal Farm, Cairo, Egypt) were housed for 1 week prior to experimentation. The environment consisted of standard mouse cages with a 12-h light/dark cycle. The temperature was 22 ± 1°C, animals had free access to water and standard laboratory pellets (20% proteins, 5% fats, and 1% multivitamins). All animal care and experiments were done in accordance with animal experiment legislation and with approval of the local ethics commission. All data were tested for significance using one-way ANOVA. A value of p < 0.05 was considered statistically significant.
Tonic extensor convulsion and toxicity tests. Male mice with an average weight of 18-22 g were used. Reference mice received a single ip injection of 2 mg/kg strychnine to determine the pharmacological end point for tonic extensor convulsions (TECs) and lethality. Control mice were injected ip with 0.1 ml external buffer, followed 30 min later by an ip injection of 2 mg/kg strychnine in external buffer. Test mice were injected ip with quercetin or genistein in doses ranging from 1 to 5 mg/kg, and 30 min later injected ip with 2 mg/kg strychnine. Mice were observed over a period of 1 h and the time until occurrence of TECs and death recorded. The first presence of tonus in the hind limbs with stretching was taken as TEC onset, whereas death, preceded by clonic convulsions and tonic seizures, was the pharmacological end point. A control group of mice was injected with quercetin or genistein only; in doses up to 5 mg/kg, neither of the flavonoids alone produced convulsions or toxicity.
Open field test. Male mice with an average weight of 18-22 g were tested individually in an open field area (35 3 20 3 20 cm) divided into four compartments. Measurements were made in the dark. Mice were placed in the test cage for 30 min prior to the experiment for habituation. Control mice were then ip injected with external buffer, test mice received ip injections of either quercetin or genistein in doses of 1-5 mg/kg. Mice were returned to the observation area immediately after injection. Total distance covered over 5 min was recorded as a measure of locomotor activity.
RESULTS
The flavonoids quercetin and genistein ( Fig. 1) have been shown to modulate GlyR function (Huang and Dillon, 2000; Lee et al., 2007; Lee et al., 2008) . It was assumed that both compounds bind to a site on the receptor that is also targeted by alcohols and local anesthetics. To investigate their mode of action and to ascertain whether there is one or several sites for inhibitors on recombinant a 1 GlyR expressed in HEK 293 cells, we studied the effects of the flavonoids alone, of both flavonoids applied together, and of flavonoids in combination with strychnine. A U-tube ligand application system (Breitinger, 2001; Krishtal and Pidoplichko, 1980 ) with a time resolution of some 30 ms for equilibration of a suspended cell with ligand solution was used. This technique had been used for the study of nicotinic acetylcholine (Udgaonkar and Hess, 1987) , GABA A (Geetha and Hess, 1992) , 5-HT 3 (Breitinger et al., 2001a) , and glycine (Breitinger and Becker, 2002b; Breitinger et al., 2004; Breitinger et al., 2001b; Breitinger et al., 2009; Breitinger et al., 2002; Grewer, 1999; Walstrom and Hess, 1994) receptors. In vitro patch-clamp results were then compared with in vivo behavioral studies of the same inhibitors on mice.
Inhibition of GlyR-Mediated Currents by Quercetin, Genistein, and Strychnine
Current responses from homomeric a 1 receptors expressed in HEK 293 cells ( Fig. 2A ) gave values of EC 50 ¼ 124 ± 16lM, n H ¼ 0.87 ± 0.09. All current responses were normalized to the 
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control current obtained at 2000lM of glycine. GlyR-mediated currents were reversibly inhibited by quercetin and genistein (Figs. 2B and C) . In the presence of a constant concentration of either inhibitor, the dose-response curve for glycine on recombinant a 1 GlyR showed moderate (maximum 3.2-fold) changes of EC 50 (Fig. 3 ). These differences, however, had no trend or dose dependence. In contrast, maximum current responses in the presence of genistein or quercetin were reduced in a dose-dependent manner, even at glycine concentrations up to 15 3 EC 50 (Fig. 3) . In the presence of 30lM quercetin, values of EC 50 ¼ 390 ± 30lM, n H ¼ 1.30 ± 0.08, and I max ¼ 0.90 ± 0.03 were observed; in presence of 100lM of quercetin, the constants were EC 50 ¼ 171 ± 57lM, n H ¼ 1.15 ± 0.29, and I max ¼ 0.58 ± 0.06 (Fig. 3A) . In the presence of 10lM of genistein, constants were EC 50 ¼ 168 ± 11lM, n H ¼ 2.03 ± 0.19, and I max ¼ 0.67 ± 0.01. In the presence of 100lM genistein, values of EC 50 ¼ 79 ± 5lM, n H ¼ 2.99 ± 0.65, and I max ¼ 0.26 ± 0.01 ( Fig. 3B) were found. The finding that I max in presence of the flavonoids remained depressed even at a supersaturating concentration of agonist was consistent with a noncompetitive mechanism of inhibition.
To verify the mode of inhibition, experiments were carried out at a constant concentration of glycine (100lM,~EC 40 ) and varying the concentration of inhibitors (Fig. 4) . Dose dependence of inhibition by quercetin, genistein, and strychnine ( Fig. 4A ) gave values of IC 50 (Que) ¼ 44.7 ± 6.1lM, IC 50 (Gen) ¼ 26.9 ± 4.1lM, and IC 50 (Str) ¼ 38.7 ± 5.3nM. Using the Cheng-Prusoff equation and EC 50 FIG. 3. Dose-response curves for glycine-evoked currents on HEK 293 cells transfected with GlyR a 1 complementary DNA. The curves were fitted using the Hill equation. All experiments were carried out at room temperature (21-23°C), À60 mV, pH 7.4. For each cell, current amplitudes at 2000lM glycine, in the absence of inhibitor, were taken for normalization and set to 1. (A) Solid squares, solid line: dose-response curve for glycine. Thirty-five responses from a total of 29 cells were used for analysis. The solid line was drawn from a nonlinear fit of the data to the Hill equation using the constants EC 50 ¼ 124 ± 16lM, n H ¼ 0.87 ± 0.09, and I max ¼ 1.0 ± 0.1. Open circles, dashed line: glycine dose-response curve in the presence of 30lM quercetin. Thirty responses from a total of 25 cells were used for analysis. The fitting parameters were EC 50 ¼ 390 ± 30lM, n H ¼ 1.30 ± 0.08, and I max ¼ 0.90 ± 0.03. Solid triangles, dotted line: glycine dose-response curve in the presence of 100lM quercetin. Twenty-eight responses from a total of 24 cells were used. The fitting parameters for the dashed line were EC 50 ¼ 171 ± 57lM, n H ¼ 1.15 ± 0.29, and I max ¼ 0.58 ± 0.06. (B) Solid squares, solid line: same as in (A). Open circles, dashed line: glycine dose-response curve in the presence of 10lM genistein. Twenty-nine responses from a total of 24 cells were used. The fitting parameters for the dashed line were EC 50 ¼ 168 ± 11lM, n H ¼ 2.03 ± 0.19, and I max ¼ 0.70 ± 0.07. Dotted line, solid triangles: glycine dose-response curve in the presence of 100lM genistein. Twenty-seven responses from a total of 22 cells were used. The fitting parameters for the dashed line were EC 50 ¼ 79 ± 5lM, n H ¼ 2.99 ± 0.65, and I max ¼ 0.26 ± 0.01.
FIG. 4.
Inhibition of recombinant a 1 GlyRs by strychnine, quercetin, and genistein. Experimental conditions were as before. The glycine concentration in all experiments was 100lM. All experiments were carried out at room temperature (21-23°C), À60 mV, pH 7.4. In panels (B-D), data from panel (A) were replotted after equation A9 (Appendix). (A) Dose-dependent inhibition of glycine-mediated currents on HEK 293 cells transfected with GlyR a 1 subunit. Solid squares, solid line: inhibition by quercetin in the presence of 100lM glycine. Thirty responses from a total of 25 cells were used for analysis. Analysis gave a value of IC 50 ¼ 44.7 ± 6.1lM, n H ¼ 1.16 ± 0.2. Using the Cheng-Prusoff equation and the EC 50 value for glycine of 124lM, a value of K i (Que) ¼ 55.8 ± 1.3lM was calculated. Dashed line, open circles: genistein dose-response curve in the presence of 100lM glycine. Twenty-nine responses from a total of 24 cells were used. Analysis gave a value of IC 50 ¼ 26.9 ± 4.1lM, n H ¼ 0.77 ± 0.1. Using the Cheng-Prusoff equation, K i (Gen) ¼ 21.6 ± 0.6lM was calculated. Solid triangle, dotted line: strychnine doseresponse curve in the presence of 100lM glycine. Twenty-seven responses from a total of 22 cells were used. Analysis gave a value IC 50 ¼ 38.7 ± 5.3nM, n H ¼ 0.55 ± 0.02. Using the Cheng-Prusoff equation, a value of K i (Str) ¼ 48.4 ± 4.0nM was calculated. (B) Inhibition of glycine-mediated currents by strychnine: linear regression of the data gave the solid line with a slope of 0.015 ± 0.001/nM and an intercept of 1.2 ± 0.1, giving K i (Str) ¼ 66.7 ± 6.1nM. (C) Inhibition of glycine-mediated currents by quercetin: linear regression of the data gave the solid line with a slope of 0.024 ± 0.001/lM and an intercept of 0.95 ± 0.05, giving K i (Que) ¼ 41.7 ± 4.0lM from the slope and using equation A9 (Appendix). (D) Inhibition of glycine-mediated currents by genistein: linear regression of the data gave the solid line with a slope of 0.023 ± 0.002/lM and an intercept of 1.2 ± 0.1 and a calculated inhibition constant K i (Gen) ¼ 43.4 ± 4.2lM.
(Gly) ¼ 127lM, K i values were estimated (Table 1) to be
Inhibition data were replotted ( Fig. 4B -D) using a current ratio equation (Appendix, equation A9) , where the control current (100lM glycine) in the absence of inhibitor (I Gly ) was divided by the current obtained with 100lM of glycine plus inhibitor (I Gly,x ). For a noncompetitive inhibitor, a plot of the current ratio I Gly /I Gly,x versus inhibitor concentration gives in a straight line with a slope of 1/K i (Appendix). From this mechanism-based analysis of the data, inhibition constants of (Fig. 4C) , and K i (Gen) ¼ 43.4 ± 4.2lM (Fig. 4D) were obtained (Table 1) in good agreement with the previous results.
It should be noted that the I Gly /I Gly,x versus [inhibitor] curves were linear over a 100-fold concentration range and remained linear at inhibitor concentration > 2 3 K i . This is compatible with a noncompetitive mode of inhibition, as a competitive inhibitor would give a square relationship (Appendix) of the I Gly /I Gly,x versus [inhibitor] curves (see Appendix) (Breitinger et al., 2001a; Karpen and Hess, 1986) . Thus, two independent sets of experiments produced consistent sets of data that could be interpreted using a simple model of noncompetitive inhibition of recombinant a 1 GlyRs by quercetin, genistein, and also strychnine.
Simultaneous Inhibition by Two Inhibitors
To identify the sites of inhibition and possible drug synergism by a kinetic approach, two inhibitors were applied simultaneously, keeping the concentration of one of them constant while varying the other (Fig. 5) . In this case, if the two inhibitors occupy the same site, the I Gly /I Gly,x versus [inhibitor] curve should be shifted upward but have the same slope. If both inhibitors bind to different sites, the inhibitory effects should potentiate each other, leading to a different higher slope of I Gly / I Gly,x plot (Appendix scheme 2, equations A10 and A11).
The slope of the ratio curve for quercetin inhibition was 0.024 ± 0.002, giving a K i of 41.7 ± 4.0lM (Fig. 4C ). In the Figure 4C . Open circles, dashed line: represent data of inhibition by quercetin in the presence of constant concentration (10lM) genistein from 2 to 7 measurements at each genistein concentration (total of 18 measurements from 23 cells). The dashed line has a slope of 0.023 ± 0.002/lM and an intercept of 1.7 ± 0.1. Using equation A10 (Appendix), K i for quercetin in the presence of genistein of 43.5 ± 4.7lM was calculated. (B) Inhibition by genistein in the presence and absence of quercetin. Solid squares, solid line: represent data of inhibition by genistein in the absence of quercetin, from 2 to 9 measurements at each genistein concentration (total of 21 measurements from 24 cells), same data as in Figure 4D . Open circles, dashed line: data of inhibition by genistein in the presence of constant concentration of (30lM) quercetin from 2 to 7 measurements at each quercetin concentration (total of 22 measurements from 27 cells). The dashed line has a slope of 0.023 ± 0.002/lM and an intercept of 1.6 ± 0.1. Using equation A10 (Appendix), an inhibition constant for genistein in the presence of quercetin of K i ¼ 43.4 ± 3.9lM was calculated.
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presence of 10lM genistein, the slope of inhibition curve was 0.023 ± 0.003, giving K i (Que) ¼ 43.5 ± 4.7lM (Fig. 5A) . Within experimental error, these values are the same, indicating that quercetin and genistein indeed target the same site on the GlyR.
The reverse experiment was done for varying concentration of genistein in the presence or absence of a constant concentration of 30lM quercetin. Genistein alone gave a slope of 0.023 ± 0.002 and gave K i (Gen) ¼ 43.5 ± 4.0lM (same data as Fig. 4C ). In the presence of 30lM quercetin, the slope of inhibition curve is 0.023 ± 0.002, giving an apparent K i (Gen) ¼ 43.5 ± 3.9lM (Fig. 5B) . Within experimental error, presence of a second flavonoid inhibitor did not alter the inhibitory potency of the other. Therefore, it could be concluded that quercetin and genistein were noncompetitive inhibitors that occupied the same site on recombinant a 1 GlyRs.
Inhibition by Strychnine and Flavonoids
In a similar manner as described before, inhibition by quercetin in the absence and presence of 16nM strychnine was studied (Fig. 6) . For quercetin alone, the slope of the inhibition curve was 0.024 ± 0.001 and K i (Que) was 41.7 ± 4.0lM (Figs. 4C and 5A ). In the presence of 16nM strychnine, the slope of inhibition curve was 0.054 ± 0.002, giving an apparent inhibition constant of K i (Que) ¼ 23 ± 1lM in the presence of strychnine (Fig. 6A ). This increase in slope and thus in apparent inhibitory potency of quercetin together with strychnine is not compatible with quercetin and strychnine binding to the same site of the GlyR.
Quercetin inhibition was also studied in the presence of both, genistein and strychnine. As shown before (Figs. 4C and 5A), quercetin inhibition was not affected by the absence (Fig. 5A , solid squares) or presence of genistein (Fig. 5A , indicated by open circles). Slopes of the ratio curves were 0.024 ± 0.002 and 0.023 ± 0.003 for quercetin alone and in presence of 10lM genistein, respectively. In the presence of 10lM genistein and 16nM strychnine, the slope of inhibition curve was increased to 0.120 ± 0.006 (Fig. 6B ), giving an apparent K i # (Que) ¼ 8.3 ± 0.4. Even in the presence of genistein, strychnine was thus able to potentiate receptor inhibition by quercetin.
Overall, the results from in vitro patch-clamp experiments indicated that strychnine was a noncompetitive inhibitor of recombinant a1 GlyRs in HEK 293 cells. The flavonoids quercetin and genistein also were noncompetitive inhibitors, targeting a different site from the one used by strychnine. Both sites could be used simultaneously, so strychnine and the flavonoids could potentiate their inhibitory effects, acting as synergistic inhibitors of the GlyR.
In Vivo Studies-Open Field Test
To verify the observed synergism in vivo, behavioral tests were performed. Locomotor activity was tested in mice that received doses between 1 and 5 mg/kg of each flavonoid (Fig. 7A ) after 30-min habituation to the test cage. Administration of quercetin and genistein alone (1-5 mg/kg ip, n ¼ 4 for each concentration) produced a robust and a dose-dependent increase in locomotor activity. Activity was especially high in the second minute postinjection (data not shown). Overall distance traveled within 5 min was recorded for both, flavonoidand vehicle-treated animals. As expected for a GlyR inhibitor, locomotor behavior was increased in the presence of both flavonoids (Fig. 7A ).
TEC and Lethality Test
When administered alone, quercetin and genistein produced some mild reversible convulsions, visible as occasional twitches. These twitches did not interfere with locomotor Figure 4C . Open circles, dashed line: represent data of inhibition by quercetin in presence of constant concentration of (10lM) genistein from 2 to 7 measurements at each genistein concentration (total of 22 measurements from 27 cells) as in Figure 5A . Solid triangles, dotted line: data of inhibition by quercetin in the presence of constant concentrations of genistein 10lM and strychnine 16nM from 2 to 7 measurements at each strychnine concentration (total of 8 measurements from 11 cells). The dotted line has a slope of 0.12 ± 0.01/lM and an intercept of 2.9 ± 0.3, giving an apparent inhibition constant for quercetin in the presence of strychnine and genistein of
activity. None of the tested animals showed any TECs, and flavonoids alone were not otherwise toxic or lethal in any of the test animals. In contrast, an injection of strychnine alone (2 mg/kg ip) was lethal in all tested animals. TEC set in after 5.6 ± 0.3 min and death occurred after 6.3 ± 0.3 min (n ¼ 4). In mice that had been preinjected with quercetin or genistein (1-5 mg/kg), the toxic effects of strychnine were aggravated in a dose-dependent manner. At the highest dose of inhibitors (5 mg/kg ip), administration of strychnine resulted in TEC already after 1.9 ± 0.1 min (quercetin) and 2.3 ± 0.1 min (genistein). Death occurred after 2.2 ± 0.1 min (quercetin) and 3.0 ± 0.1 min (genistein), overall a 2-to 3-fold increase in the time course of strychnine action.
Therefore, it could be concluded that flavonoids alone, in doses that were harmless to mice, produced only a transient increase in locomotor activity and mild occasional twitches, as expected for a GlyR inhibitor. However, when given together with strychnine, flavonoids increased the toxicity of the latter. Overall, in vitro and in vivo data showed that flavonoids and strychnine are noncompetitive inhibitors of spinal cord GlyRs, binding to distinct sites on the receptor. Inhibition by flavonoids and strychnine is synergistic, i.e., presence of one inhibitor augments inhibitory potency of the other.
DISCUSSION
It has been shown previously that quercetin and genistein are inhibitors of spinal cord GlyRs (Huang and Dillon, 2000; Lee et al., 2007; Lee et al., 2008) , but their detailed mode of inhibition was not studied so far. Here, we illustrate that quercetin and genistein act as noncompetitive inhibitors on GlyR a1-mediated currents, both targeting the same site on the receptor. Coapplication with strychnine revealed that the flavonoid-binding site is different from the strychnine site. The identification of these different binding sites was done using a mechanism-based approach that does not require structural information. Toxicological and behavioral tests on mice confirmed this pattern of flavonoid action and revealed a similar synergism of inhibition by flavonoids and strychnine in vivo.
Glycine dose-response curves showed a dose-dependent reduction of maximum currents in the presence of quercetin or genistein, which persisted at all concentrations of agonist. In contrast, changes in EC 50 did not show a consistent trend or dose relationship. This observation would be compatible with a noncompetitive mode of inhibition. Noncompetitive inhibition of the flavonoids was also observed in an independent set of experiments, where the concentration of inhibitor was varied at a constant concentration of glycine. The resulting inhibition curves were compatible with a noncompetitive mode of inhibition. Our observations extend the previous observations of flavonoid inhibition of the GlyR (Huang and Dillon, 2000; Lee et al., 2007; Lee et al., 2008) , classifying quercetin and genistein as noncompetitive inhibitors.
Strychnine inhibition of GlyRs has been known and studied for a long time. Both competitive (O'Connor et al., 1996) and noncompetitive (Davidoff et al., 1969) actions for strychnine inhibition of GlyRs have been reported. To date, a model where strychnine binds to a site that is partially overlapping with, but not identical to the glycine-binding site is generally accepted (Breitinger and Becker, 1998, 2002a) . In this study, strychnine inhibition data could be described by a noncompetitive mechanism of inhibition. Strychnine antagonism may be more complex, as different modes of inhibition were observed, which may also depend on the technique used. In this study, we chose the simplest model that describes the data satisfactorily. Furthermore, the current ratio technique used here would reveal whether two inhibitors bind to the same or to different sites irrespective of their mode of inhibition.
Coapplication of strychnine with quercetin or genistein, or both, showed that the inhibitory potency of each flavonoid was increased in the presence of strychnine. These data indicated toxsci.oxfordjournals.org that strychnine binds to a different site than quercetin and genistein. Binding of two drugs to different independent sites on their target receptor is a necessary requirement for true synergism (Hess et al., 2000; Tallarida, 2001) . Here, presence of one drug (strychnine) did increase the extent of inhibition mediated by the other (quercetin or genistein). This observation would be true if strychnine alone inhibited GlyRs by competitive or noncompetitive antagonism or by a combination of both mechanisms. Similar results had been published for serotonin 5-HT 3 receptors on NIE-115 cells, where cocaine and nicotine bind to the same site on the receptor, which is different from the site for fluoxetine (Breitinger et al., 2001a) and for the inhibition of nicotinic acetylcholine receptors by cocaine, phencyclidine, and procaine (Karpen and Hess, 1986) .
The synergism indicated by our in vitro patch-clamp studies was further verified in a mouse model in vivo. Both, quercetin and genistein, showed an increase in overall locomotor activity in the open field test, as expected for a GlyR inhibitor in sublethal dosage. Both flavonoids were not harmful or toxic in any way to the mice tested. At concentrations up to 5 mg/kg, some slight twitches were observed, but no convulsions or lethality. An epileptogenic activity of Gingko biloba flavonoids had been reported previously (Ivetic et al., 2008) . Indeed, the mild tremors observed in our experiments could be thus interpreted. However, at the doses used here, these tremors were brief, lasting not more than a minute on average, and had no notable effect on animal behavior or well-being. Strychnine, on the other hand, was lethal within 6 min at the concentration tested (2 mg/kg), and death was preceded by TECs. When animals were treated with quercetin and genistein prior to strychnine application, the toxicity of strychnine was dramatically and dose dependently increased. At the highest dose of flavonoids (5 mg/kg ip), time until onset of TEC and death was decreased by 2-to 3-fold. The increase in strychnine toxicity by nonharmful doses of flavonoids is a clear example of synergistic inhibition. Additive effects of inhibition resulting from simultaneous application of quercetin and genistein have been reported previously (Lee et al., 2008 ), yet not studied further. Our results indicate that the observed increase in inhibition is an additive effect resulting from a higher effective concentration of inhibitor being present, but not the result of synergistic action of quercetin and genistein.
Study of the effects of multiple drugs given simultaneously and synergistic action of drugs are fields of increasing importance, as pharmaceuticals often exert unexpected effects when given in combination. Since drugs usually affect entire biochemical pathways, not only individual targets, even the selection of appropriate models is difficult. Consequently, proposed mechanisms of synergism and methods of their investigation are numerous (Berenbaum, 1989; Chou, 2006; Tallarida, 1992 Tallarida, , 2001 . A simple additive effect (i.e, A þ B > A), as often observed when several drugs are administered simultaneously, tells ''nothing about synergism. This is a simple arithmetic fact . . .'' (Chou, 2006) . Here, we used a mechanismbased approach that identifies whether two inhibitors bind to the same or to different sites on their target protein. Two drugs can only act synergistically, if they bind to different sites, as had been shown for the inhibition of nicotinic acetylcholine receptors and serotonin 5-HT 3 receptors (Breitinger et al., 2001a; Hess et al., 2000; Karpen and Hess, 1986) . Here, we have chosen a minimum model (Scheme 1) to describe ion channel function, which assumes independent binding of two agonist molecules prior to channel opening (Breitinger et al., 2001a; Hess et al., 2000; Karpen and Hess, 1986; Katz and Thesleff, 1957) . This model already constitutes a simplification yet has been found sufficient to describe activation of ligandgated ion channel receptors. Our treatment of receptor inhibition was incorporated into the same model.
The data recorded from patch-clamp experiments suggested that genistein and quercetin both target the same site on the GlyR, their coapplication would be an example of dose additivity or Loewe additivity (Berenbaum, 1989; Loewe, 1953) , with binding of genistein or quercetin being mutually exclusive (Fitzgerald et al., 2006; Tallarida, 1992 Tallarida, , 2001 ). Inhibitory potency of either flavonoid is the same in the absence or presence of the other one, and coapplication of both flavonoids (Fig. 5 ) results in dose-additive inhibition. Coapplication of strychnine and flavonoids, on the other hand, showed distinctly different characteristics. Inhibitory potency (given as apparent K i ) of flavonoids was increased in the presence of strychnine (Fig. 6 ). This was treated as a case of Bliss independence, also termed response additivity (Bliss, 1939) , with strychnine and flavonoids binding independently (mutually nonexclusive) to different target sites on the receptor (Berenbaum, 1989; Fitzgerald et al., 2006; Tallarida, 1992 Tallarida, , 2001 . Synergism is observed as the receptor can enter an additional set of inhibited states (XYR, XYRL, XYRL 2 , XYRL 2 [closed] in Scheme 2). These additional states are only available if both inhibitors are present, resulting in the observed superadditivity or synergism of inhibition between flavonoids and strychnine (Berenbaum, 1989; Segel, 1975) . A less modelbased definition describes synergism to occur when ''. . . the combined effect of two chemicals is greater than the sum of the effects of each chemical given alone'' (Nielsen et al., 2008) . This criterion was fulfilled for the combination of strychnine and flavonoids. Our in vivo toxicity tests agreed with the postulated synergism of receptor inhibition by flavonoids and strychnine. Here, flavonoids alone were nonlethal (zero toxicity), whereas application of strychnine alone resulted in convulsions and death within~6 min. However, upon coapplication, the same doses of flavonoids augmented the toxicity of strychnine some 3-fold (Fig. 7B ). This superadditive effect would even satisfy the criterion of potentiation as a form of synergism, which ''. . . occurs when the toxicity of a certain chemical on a tissue or organ system is enhanced when given together with another chemical that does not have toxic effects on the same tissue or organ system'' (Nielsen et al., 2008) .
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In a mechanism-based approach, we could identify the existence of different drug-binding sites for the flavonoids quercetin and genistein and for the alkaloid strychnine. This proved to be a necessary and sufficient condition for flavonoids and strychnine to act in a synergistic manner as inhibitors of GlyRs in vitro and in vivo. The approach presented here allows the identification of drug target sites and the prediction of potential synergistic effects of drug combinations from a set of readily obtained functional data. 
APPENDIX
Mechanisms and Equations used for data analysis (see also Breitinger et al., 2001a; Karpen et al., 1982; Karpen and Hess, 1986) The classical scheme of ligand-gated ion channel activation (Katz and Thesleff, 1957) , requiring the binding of two ligand molecules prior to channel opening was used (scheme 1). The minimum model we used assumes that both activating ligands bind independently from each other and both binding steps have the same K D (Hess, 2003 
Using the mass action equations
and / ¼ RL 2 RL 2 ðopenÞ ; ðA3BÞ equation A1 becomes the dose-response equation (Hess, 2003) :
In the presence of a competitive inhibitor (C), the doseresponse equation becomes (Karpen et al., 1982) 
where C is the competitive inhibitor and K C is its dissociation constant from the receptor. In the ratio approach, one divides the current I Gly , obtained in the absence of inhibitor by the current I GLy,C , measured in the presence of the competitive inhibitor. This ratio is (Breitinger et al., 2001a) 
F A and F AL are the fractions of unliganded and singly liganded receptor, respectively,
and
Note that the current ratio gives a square dependence on the concentration of inhibitor (equation A6). A plot of I Gly /I Gly,C versus [C] should, therefore, result in a nonlinear curve.
SYNERGISTIC INHIBITION OF GLYCINE RECEPTORS
The mechanisms of noncompetitive inhibition by one or two inhibitors are shown below (scheme 2). X and Y denote the inhibitors; for simplicity, one binding site per receptor complex is assumed. The mechanism for two noncompetitive inhibitors binding to the same site is denoted in black. Note the presence of additional inhibited states in the case of two inhibitors binding to different sites on the receptor (gray). In all situations, presence of an inhibitor prevents the receptor channel from opening, so is the only conducting, open-channel state of the receptor.
Scheme 2: Mechanism of noncompetitive inhibition by one or two inhibitors (Breitinger et al., 2001a; Karpen et al., 1982) :
The dose-response curve in the presence of one noncompetitive inhibitor X with a dissociation constant K X is as follows:
which gives a current ratio of
Note that the current ratio remains a linear function of inhibitor concentration over the entire concentration range, different from the situation of competitive inhibition.
If two noncompetitive inhibitors, X and Y, are present, which both bind to the same site on the receptor, both inhibitors will compete for this site. In this case, the current ratio is
If [Y] were varied, presence of a constant concentration of [X] would only result in a shift of the intercept, but the slope of the ratio curve I Gly /I Gly,Y versus [Y] would be the same in the presence or absence of X.
In the presence of two inhibitors X and Y, which bind to distinct, independent sites on the receptor, the current ratio becomes
Here, both slope and intercept of the plot of I Gly /I Gly,Y versus [Y] would be increased in the additional presence of the second inhibitor X.
